ES002

ES002 is an investigational **anti-CD39 monoclonal antibody** developed by **Elpiscience Biopharmaceuticals** for the treatment of **advanced solid tumors**. The antibody is designed to inhibit **CD39**, an ectonucleotidase that converts extracellular ATP and ADP toward immunosuppressive adenosine production in the tumor microenvironment. By blocking CD39 activity, ES002 is intended to preserve pro-inflammatory extracellular ATP signaling and restore anti-tumor immune responses. Publicly described development has included Phase 1 evaluation in the United States and China, with studies in patients with advanced solid tumors such as pancreatic ductal adenocarcinoma, non-small cell lung cancer, and colorectal adenocarcinoma.

Other names

anti-CD39 monoclonal antibodyanti-CD-39 monoclonal antibodyanti-CD 39 monoclonal antibody